Anti-Omalizumab ELISA Kit

Catalog No.

KAJ92701

Description

PRINCIPLE OF THE ASSAY This assay employs the quantitative sandwich enzyme immunoassay technique. Omalizumab has been pre-coated onto a microplate. Samples or standards are pipetted into microwells and Anti-Omalizumab will be captured by immobilized Omalizumab. After washing away any unbound substances, a biotin-labeled Omalizumab is added to the wells. After washing away any unbound substances, Streptavidin-HRP is added to the wells. Following a wash to remove any unbound enzyme reagent, a substrate solution is added to the wells and color develops in proportion to the amount of Anti-Omalizumab bound in the initial step. The color development is stopped and the intensity of the color is measured.

Applications

Used for the quantitative determination of Anti-Omalizumab concentration in serum and plasma.

Detection method

Colorimetric

Sample type

Plasma, Serum

Assay type

Quantitative

Range

0.78 - 50 ng/mL

Sensitivity

0.32 ng/mL

Precision

Intra-Assay Precision (Precision within an assay): <10%

Three samples of known concentration were tested sixteen times on one plate to assess intra-assay precision.

Inter-Assay Precision (Precision between assays): <15%

Three samples of known concentration were tested in twenty four separate assays to assess inter-assay precision.

	Intra-Assay Precision			Inter-Assay Precision
Sample	1	2	3	1	2	3
n	16	16	16	24	24	24
Mean (ng/mL)	26.8	5.6	2.1	23.5	6.9	2.2
Standard deviation	2.3	0.3	0.2	2.1	0.5	0.3
CV (%)	8.5	6.2	7.7	8.9	7.1	14.8

Recovery

80-120%

Shipping

2-8 ℃

Stability and Storage

When the kit was stored at the recommended temperature for 6 months, the signal intensity decreased by less than 20%.

Alternative Names

IGE25,olizumab,pSVIE26,rhuMab-E25,CAS: 242138-07-4

Describing Clinical Characteristics and Treatment Course of Patients with Hereditary Alpha-tryptasemia: A Single-center Study., PMID:40515774

Biologics in IgE-mediated food allergy: A systematic review and meta-analysis of interventional studies., PMID:40510735

Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity Profiles of a Single-Dose JYB1904 in Healthy Chinese Participants: A Phase Ia, Randomized, Double-Blind, Placebo-Controlled Study., PMID:40504164

Health care resource utilization of patients with asthma and food allergy initiating omalizumab., PMID:40497014

Corrigendum to "Omalizumab may protect allergic patients against COVID-19: A systematic review" [World Allergy Organ J 16 (2) (2023) 1-19]., PMID:40496753

Comparative Analysis of ICS Combined with LABA versus Addition of Omalizumab on Transcriptomic Expression Profiles in Patients with Allergic Asthma., PMID:40491983

Aspirin-Exacerbated Respiratory Disease in the era of biologics., PMID:40490219

Advancements in Biologic Therapies for Pediatric Asthma: Emerging Therapies and Future Directions., PMID:40486460

Identification of the Top 15 Drugs Associated With Anaphylaxis: A Pharmacovigilance Study., PMID:40484712

A nationwide experience of biological treatments in children with eosinophilic esophagitis., PMID:40483369

How to manage hypersensitivity reactions to enzyme replacement therapy in lysosomal storage diseases?, PMID:40481554

Prognostic calculator of the clinical response to antihistamines in chronic urticaria: External validation., PMID:40480548

Azathioprine for the Treatment of Chronic Spontaneous Urticaria Refractory to Antihistamines, Omalizumab, and Ciclosporin: A Case Series., PMID:40480489

Equivalence of SYN008 versus omalizumab in patients with refractory chronic spontaneous urticaria: A multicenter, randomized, double-blind, parallel-group, active-controlled phase III study., PMID:40474341

The Efficacy of Different Dosing Regimens of Omalizumab in children and adolescents with chronic spontaneous urticaria based on real-life data., PMID:40466628

In brief: Omlyclo - an omalizumab biosimilar interchangeable with Xolair., PMID:40459407

Evaluating remibrutinib in the treatment of chronic spontaneous urticaria., PMID:40455080

Efficacy and safety of CT-P39, an omalizumab biosimilar, in chronic spontaneous urticaria: 16-week follow-up study., PMID:40454995

Hereditary alpha-tryptasemia - a potential cause of severe anaphylactic reactions and a modifier of mast cell diseases., PMID:40450750

Introduction of Allergenic Foods After Treatment with Omalizumab., PMID:40447195

Efficacy and safety of Omalizumab in the treatment of CSU: a meta-analysis of a randomized controlled trial., PMID:40439896

Omalizumab Efficacy in Chronic Rhinosinusitis Patients with Recurrent Nasal Polyps: An open-label, single-center, randomized, controlled study., PMID:40437843

Omalizumab in Food Allergy in Children: Current Evidence and Future Perspectives., PMID:40430110

Four-week IgE/baseline IgE ratio combined with tryptase predicts clinical outcome in omalizumab-treated children with moderate-to-severe asthma., PMID:40417314

Anti-KIT Barzolvolimab for Chronic Spontaneous Urticaria., PMID:40415544

Treatment of eosinophilic dermatosis of hematologic malignancy with omalizumab., PMID:40413842

Redefining Omalizumab Discontinuation in Chronic Spontaneous Urticaria: The Value of Optimization and Predictive Factors of Relapse. A 52-Week Multicenter Study., PMID:40403841

Bioinformatics analysis of FCER1A as a key immune marker in dilated cardiomyopathy and systemic lupus erythematosus., PMID:40401008

Both Extrinsic and Intrinsic Atopy in Chronic Spontaneous Urticaria Patients Indicate a Favorable Response to Omalizumab Treatment., PMID:40397623

Resolution of Patient's Anaphylaxis to the Moderna COVID-19 Vaccine by Desensitization., PMID:40386747

Anaphylaxis in children: Latest insights., PMID:40380371

Value-based care in allergy-immunology: Beyond the quality-adjusted life year., PMID:40380361

Emerging Therapies in the Treatment of Prurigo Nodularis: Biological Therapy and Systematic Review of Literature., PMID:40372666

Biologic Therapies for Severe Asthma: Current Insights and Future Directions., PMID:40364184

Omalizumab dosing patterns and drug survival in adult patients with chronic spontaneous urticaria., PMID:40357715

Combination of Allergen-Specific Immunotherapy With Biologics in Severe Asthma: Counterintuitive or Rational?, PMID:40349962

Requalification of patients with severe asthma for biological therapy-Practical 'ReQuaBi' rate decision scheme based on the analytical model., PMID:40348613

Reappraisal of Biologic Efficacy from Phase 3 Trials in Refractory Chronic Rhinosinusitis and Nasal Polyps., PMID:40340024

Omalizumab: a broader role in dermatology? Evidence and the road ahead., PMID:40338196

Pityriasis rosea-like eruption induced by omalizumab: a case report of a rare side effect., PMID:40330944

Scientific developments in understanding food allergy prevention, diagnosis, and treatment., PMID:40330465

Biological and target synthetic treatments for chronic spontaneous urticaria: A systematic review and network meta-analysis., PMID:40326848

Spectrum and Impact of Reported Side Effects of Omalizumab in Patients With Chronic Urticaria: A Long-Term Multicentre Real-World Study., PMID:40325793

Glycobiology of IgE., PMID:40322856

Recurrent Chronic Idiopathic Urticaria Post-hysterectomy and Loss of Xolair Effectiveness: A Case Report., PMID:40322383

Structural and Functional Insights Into IgE Receptor Interactions and Disruptive Inhibition., PMID:40305523

Efficacy of tiotropium bromide on spirometric measurements and control of asthma in real life: data from a 1-year clinical follow-up., PMID:40304436

Mental Health Interventions in Refractory Chronic Spontaneous Urticaria: A Call to Expand Treatment Guidelines., PMID:40303526

Secukinumab as a Novel Treatment for Chronic Netherton Syndrome in a Young Adult., PMID:40299794

Research progress of anti-IGE treatment for allergic rhinitis., PMID:40286545

Document Download

Anti-Omalizumab ELISA Kit.pdf